The just-released MACRA final rule will be particularly important to ophthalmologists, who often have a Medicare-heavy patient base. Medscape Medical News
Uncategorized
Treat-and-extend dosing reduces treatment burden in TREX-AMD trial
CHICAGO — Treatment burden was significantly reduced with treat-and-extend dosing vs. monthly dosing of ranibizumab through 2 years in the TREX-AMD study, an investigator reported here. Charles C. Wykoff , MD, PhD, presented the study results at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting. The trial was funded by a grant from Genentech.
Uncategorized
Brimonidine seen as promising treatment for geographic atrophy
CHICAGO — Neuroprotective brimonidine as a treatment for geographic atrophy is promising, William R. Freeman, MD, told colleagues at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting.Freeman reported results of a phase 2 randomized clinical trial of brimonidine administered intravitreally using a 22-gauge insert placed in the eye that released brimonidine over a period of 6 months. Allergan sponsored the trial.
Uncategorized
Compact Navilas laser system introduced to non-US market
CHICAGO — OD-OS introduced its new compact Navilas laser system to non-U.S. markets here at the American Academy of Ophthalmology meeting.The Navilas 577s, a retinal photocoagulator with a digital fundus camera, is to be used in retinal laser treatments, as well as the diagnosis and treatment of ocular pathology in the posterior segment, according to a company press release.
Uncategorized
Valeant CEO: More efficient, available health care needed
CHICAGO — Making health care more efficient and access to that health care more available as the population ages has become an important factor for the companies involved in pharmaceuticals and technology, Joseph Papa, chairman and CEO of Valeant Pharmaceuticals, said during a press briefing here.In discussing Valeant and Bausch + Lomb’s strategies for addressing these trends, Papa said that consumption of eye care drugs and treatments is 7.8 times greater in persons older than 60 years of age than in those who are younger.
Uncategorized
Lumenis launches Smart 532 photocoagulator
CHICAGO — Lumenis announced the launch of a new photocoagulator at the American Academy of Ophthalmology meeting here.The Smart 532 photocoagulator is powered by SmartPulse sub-threshold technology and includes a new user interface and touch screen, according to a company announcement.